The Case for Abandoning Induction Chemotherapy
Dr. Pollyea discusses reconsidering the treatment of acute myeloid leukemia solely with intensive induction chemotherapy.
Another Therapeutic Agent in the Pipeline for Preventing Acute Vaso-Occlusive Events in Sickle Cell Disease
Dr. DeBaun looks at experiments using ARQ 092 as a possible therapeutic agent for preventing acute vaso-occlusive events in sickle cell disease.
Drs. Moll and Reeves look at anticoagulation failures in VTE and whether JAK2 V617F and CALR mutation screening should be required.
Two new podcasts provide an overview of the ASH Honorific Awards and discuss genetic profiling to guide SCT in MDS.
Dr. Pollyea discusses reconsidering the treatment of AML solely with intensive induction chemotherapy.
May/June 2017 Volume 14, Issue 3
View all Features articles
View all Diffusion articles
Dr. Kenneth Anderson discusses ASH's participation in the March for Science as well as the Society's advocacy efforts for hematology research funding.
View all president's column articles
View all Ask the Hematologist articles
View all Op-Ed articles
View all Mini Review articles
The House of Representatives released legislation, titled
the “American Health Care Act,” to repeal the Affordable Care Act. As
written, ASH has serious concerns that this legislation will reduce overall
access to coverage and treatment and would greatly impact patients with
hematologic diseases and disorders.
Through a notice on its website, the Drug Enforcement Administration (DEA) recently announced significant changes to its registration renewal process. Effective January 1, 2017, the DEA is eliminating the informal grace period which the agency has previously allowed for registrants to renew their registrations.
On December 15, 2016, the Centers for Medicare and Medicaid Services (CMS) announced the cancellation of Medicare Part B Drug Payment Model. CMS initially proposed the demonstration on March 8, 2016 to test new models in how physician-administered drugs are paid under the Medicare program.
ASH is pleased to see the National Heart, Lung and Blood Institute’s (NHLBI) continuous support (RFA-HL-15-030) for the development of improved techniques to enhance the production of clinically relevant, functional stem cell-derived red blood cells or platelets.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology